Cataract surgery blitz for Indigenous patients restores sight for hunting
Scrub nurse Peter Mitchell anticipates which tool the surgeon will need next, as he carefully makes a small incision in a patient's eye.
"Being in theatre in this situation, it's a really beautiful feeling — a real sense of flow and understanding," he says.
But these are tricky cases.
The patient on the table has a dense cataract that has gone untreated for some time.
"Very, very seldom do you see a cataract as hard as this down south, but they're relatively common in the sorts of areas we're in now," Mr Mitchell says.
Patients have been flown and driven into Katherine from remote communities across the Big Rivers region of the Northern Territory for an intensive week of surgeries, conducted by the Indigenous and Remote Eye Service.
Over two days, cataracts will be removed from 27 eyes, in some cases bringing patients back from the brink of blindness.
One of the patients is Mildred Hector, a Bilinarra woman from Nitjpurru, formerly known as Pigeon Hole.
She had been struggling with hunting and fishing, with her vision in one eye obscured by cloudy cataracts.
"When I go hunting … nice eye I can look, other one no good," she says.
Her friends had noticed she sometimes had trouble seeing them too.
Now, after her surgery, she's able to read some of the smallest letters on the eye test chart.
And she's looking forward to putting her new vision to the test back home.
"It's good. We'll go fishing … get barramundi, long ones, and turtles."
The eye doctors say while patients in Sydney and Melbourne will sometimes joke that they can now see their wrinkles more clearly, it's common for Indigenous patients in the Top End to talk about things like hunting.
"It's always exciting to see the patients smiling when we remove the patch over the eye," surgeon Susith Kulasekara says.
"There are so many ways it can improve the patient's quality of life. Often driving, the patients say … and caring for their family."
Director of primary health care in the Big Rivers region, Antony King, says cataract surgeries are "immediately rewarding" for patients and staff at the hospital.
"It's not something that's seen often," he says.
Cataracts are the leading cause of blindness for Indigenous adults and are responsible for a sizeable chunk of the eye health gap.
As the clouding of the lens in the eye progresses gradually, often affecting both eyes, many remote patients don't realise how bad their vision has become until they get a visit from a travelling optometrist.
And then there are all the challenges of traversing hundreds of kilometres for a surgery, on poor-quality roads that often close during the wet season.
Health workforce data shows 1,004 ophthalmologists practising in Australia as of 2023, with only seven of those in the vast Northern Territory.
The Indigenous and Remote Eye Service, known as IRIS, is a federally funded program bringing eye surgeons to the outback to tackle the backlog of cases.
"The distribution of the clinicians that are needed to deliver these services has contracted in Australia … over a number of decades," Tim Gallagher, chief executive of Brisbane-based Vanguard Health, which delivers the program, says.
Mr Gallagher says patients will sometimes be on the waiting list for two to three years before they can be seen.
Getting dozens of remote residents to the hospital on one day is an enormous logistical challenge, especially when some people don't use mobile phones and move from place to place.
The program has succeeded by performing more than 800 cataract surgeries since mid-2023. It will now attempt to complete a further 800 during the next two years.
Dr Kulasekara says word spreads about how straightforward and painless the procedure is when patients return to their community.
"They become ambassadors," he says.
While most of the IRIS patients are Aboriginal, some are not, such as 83-year-old Katherine resident Peter Wilson.
He says the transformation of his vision after having cataracts removed from both eyes has been astonishing.
"I just couldn't believe how bright everything was, the colours," he says.
Mr Wilson says he does most of the vacuuming around his house but was increasingly missing spots.
"I'll be told by my wife, 'That's still a bit dirty, can't you see that?'" he laughs.
"So that is the sort of thing that I think will make a difference. I won't miss bits."
As fellow patient Mildred Hector leaves to catch her plane back to her community of Nitjpurru, she grabs one of the eye doctors for a parting hug.
"Thank you my dear, enjoy your vision," the doctor says.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

News.com.au
15 minutes ago
- News.com.au
Health Check: On Lamington Day, biotechs serve up their chocolate-dipped quarterly morsels
Today's news is all sweet on trial progress, revenue and cash Amplia to raise capital after runaway share performance Tryptamine starts binge eating 'magic mushie' trial Today is National Lamington Day and biotechs are serving up a solid sponge-like base of news encased in chocolate and coconut – occasionally interspersed with a jam layer. Hold the cream and pink jelly though – it just doesn't work. Like so many drug discoveries, the lamington had serendipitous origins. The story goes that one of Queensland governor Lord Lamington's maids was serving up a yellow sponge, but accidentally dunked it into molten chocolate. Lord Lammo recommended the squares to be rolled into coconut shavings for ease of eating – and the rest is history. As is this non-sequitur. Now onto the biotech news. Lumos glows after last week's mega deal Point-of-care diagnostics house Lumos Diagnostics (ASX:LDX) reports revenue of $12.4 million for the year to June 30, up 12%. June quarter revenue declined 26% to $2.6 million, owing to the end of the US flu season. Lumos reported cash outflows of US$1.7 million for the quarter, taking June 30 cash to US$2 million. Investor interest has focused on last week's mega US distribution deal with Phase Scientific, which could deliver Lumos up to US$317 million ( $487 million) over six years. This pertains to the company's bacterial-versus-viral rapid lateral flow test, Febridx. Lumos has also signed a term sheet for a $5 million loan facility, proffered by shareholders Tenmile Ventures (Andrew Forrest) and Ryder Capital. At its discretion, Lumos can draw down the facility over the next 12 months. Cleo eyes FDA approval for ovarian cancer assay Still on diagnostics, Cleo Diagnostics (ASX:COV) says it aims to submit a US Food & Drug Administration (FDA) marketing approval application for its ovarian cancer assay next year. The company is on track to complete a supportive US trial in the December quarter. Thanks to government grants and tax incentives, Cleo reported cash inflows of $38,000, taking end of quarter cash to $6.46 million. Turning to drug development, genetic disease specialist PYC Therapeutics (ASX:PYC) reports cash outflows of $17.6 million. At quarter's end the company still had cash of $153 million. The company has dosed the first patient in a combined phase 1a/2b trial for polycystic kidney disease. PYC has achieved 'alignment' with the FDA on the structure of a registrational trial for its lead program, the blinding eye disease retinitis pigmentosa type 11. The company believes the regulator will require only a phase II trial. Tryptamine BEDS down eating disorder trial Psychedelic medicines house Tryptamine Therapeutics (ASX:TYP) has started recruiting patients for a world-first binge eating disorder (BED) study. In the open-label trial, 12 patients will be administered intravenously infused psilocybin, combined with psychotherapy. Melbourne's Swinburne University is undertaking the study, with first dosing this quarter and top line results due by the end of the year. BED is the most common eating disorder in the US and second most prevalent in Australia here. The condition can result in depression, anxiety, post-traumatic stress disorder and compulsive behaviour. Amplia passes the hat Meanwhile Amplia (ASX:ATX) shares this morning entered trading halt, ahead of a share placement and share purchase plan. Amplia thus continues the rich tradition of companies leveraging clinical trial results, in this case its stunning data for hard-to-treat pancreatic disease. Amplia has reported 17 'partial response' rates in it Accent trial, in 17 out of 55 advanced disease patients. A confirmed partial response is tumour shrinkage of more than 30%, sustained for two or more months with no new cancerous lesions detected. Amplia is testing AMP-945 (narmafotinib). AMP-945 appears to inhibit the protein FAK, which is overexpressed in pancreatic cancers. Amplia shares have surged 376% in the past 12 months, but investors still value the company at a modest $110 million. As of the end of March, Amplia had cash of $10.8 million. 'Perplexed' Imugene laments soft-as-a-sponge share price Imugene (ASX:IMU) chairman Paul Hopper hopes the company's lamington-soft share price will 'do an Amplia' (our words) and reflect the company's progress with its multiple cancer trials. The company last Monday announced its phase 1b study for an aggressive blood cancer had resulted in two additional 'complete responses' (that is, the tumours disappeared). Imugene is trialing Azer-cel, its allogeneic Car-T drug made from healthy donor T-cells rather than the patient's. Naturally, Imugene announced a $22.5 million and share purchase plan for up to $15 million. On reinstatement, the shares lost 4.5 cents, or 10%, taking the loss over the past year to around 80%. This allows for a one for 34 share consolidation. 'We are very disappointed with the share price performance,' Hopper says. 'We are perplexed why we had such a lukewarm reception to the earlier data at the start of year.' Cashed up for pivotal trial But with the share raising in train, Imugene investors should no longer fear that such a dilutionary event is around the corner. Post raising Imugene should have cash of $64 million, with management costing a 60-80 patient pivotal trial at $30-40 million. If approved, Azer-cel would be the first commercial allogenic Car-T treatment, enabling mass produced, off-the-shelf therapies. 'We are in active discussions with partners on the strategy for developing the drug and getting it approved,' Hopper says. Shares settle in orbit after last week's Meso-blast off Mesoblast (ASX:MSB) shares have taken a breather after Friday's 35% surge on the back of initial US sales of its first US-approved stem cell product. The company reported unaudited June quarter revenue of US$13.2 million ($20.3 million) for Ryoncil, its treatment for childhood graft-versus-host disease. The FDA approved Ryoncil in December last year. Mesoblast founder and CEO Prof Silviu Itescu points to higher sales in the current quarter, given US Centres for Medicare and Medicaid Services coverage became effective on July 1. The company has signed up more than 25 transplant centres and hopes to enlist all 45 priority centres by October. Bell Potter analyst John Hester says the sales were in line with the firm's expectations. 'The figure is inclusive of sales to the distributor, nevertheless it represents a reasonable proxy for hospital demand.' The firm values Mesoblast at $3.50 a share, implying 55% of upside.

News.com.au
35 minutes ago
- News.com.au
Kmart August Living range reveals bold new red decor trend
For years, it has been all about neutral tones and capsule wardrobes, but finally that trend is being ditched thanks to an 'unexpected' addition. Kmart launched its August Living range, set to hit stores on July 24, and while neutral tones were still very much present it seemed this season was all about colour. For those unsure how to bring a pop of colour into their home, Kmart buyer Nic Holmes recommended the 'unexpected red theory'. The theory refers to a design concept popularised by Taylor Migliazzo Simon, which is the idea that a touch of red can make any space feel more vibrant, stylish and pulled together. This is because the colour instantly demands attention and draws the eye in. It purposefully goes against what we've been told for half a decade — that we should be trying to make our homes as neutral as possible. 'We're seeing some very viral moments — so anything red, this 'unexpected red theory' that's coming through,' the longtime Kmart buyer told The budget retailer has brought red into store in small ways, such as the $19 Nico Portable Rechargeable Lamp and the $39 Hourglass side table. 'They're small pieces where you can introduce red into your home without significant investment,' he said. 'Layering these berries and reds is becoming a real theme of the season.' Mr Holmes said customers did love the peeled back, neutral tones but the global trend was shifting towards dopamine decor — putting items you love in your home to make it more inviting and ditching trends in favour of what brings you joy. 'It's about being able to introduce colours into your home and making that very big statement away from what you're used to seeing,' he said. 'And you don't have to spend a lot of money to sneak in a dopamine piece — a cushion is enough. You can bring in side tables, you can bring in different pieces. 'And once you get comfortable with that, you can really layer on. We started introduce a bit of colour last season, and there was a lot of appetite for it.' Kmart's latest range features green, blue, red, pink and mustard yellow all for the sake of that dopamine decor trend. He said Kmart saw that, and decided to run with it. Mr Holmes said it is something he is expecting to see a lot more of in coming collections. Last year, Isfira Jensen, CEO and principal interior designer at Jensen & Co. Interiors, told ELLE that dopamine decor was a 'much needed' trend after years of neutral and minimalism.


SBS Australia
an hour ago
- SBS Australia
Vibha wanted to honour her mother's wish to die voluntarily at home. She found help online
Disclaimer: The opinions in this podcast are general and non-binding. For specific advice, please consult your General Practitioner or health expert. LISTEN TO SBS Hindi 17/07/2025 19:51 Hindi LISTEN TO SBS Hindi 14/07/2025 19:09 Hindi